Узбекистан - русский - Oʻzbekiston Respublikasi Sogʻliqni saqlash vazirligi (Министерство здравоохранения Республики Узбекистан)

Нанолек,ООО - ramipril - Таблетки 2,5 мг, 5 мг, 10 мг n7 (1х7), n10 (1х10), n14 (2х7), n20 (2х10), n21 (3х7), n28 (4х7), n30 (3х10), n35 (5х7), n40 (4х10), n50 (5х10) (контурно-ячейковые упаковки) - Антигипертензивное средство (ингибитор АПФ)

Узбекистан - русский - Oʻzbekiston Respublikasi Sogʻliqni saqlash vazirligi (Министерство здравоохранения Республики Узбекистан)

sandoz pharmaceuticals d.d., Словения произведено: lek s.a. - ramipril - Таблетки 5 мг n20 (2х10), 10 мг n100 (10х10) (блистеры) - Антигипертензивное средство (ингибитор АПФ)

Узбекистан - русский - Oʻzbekiston Respublikasi Sogʻliqni saqlash vazirligi (Министерство здравоохранения Республики Узбекистан)

radiks, ooo - ramipril - Таблетки 5 мг, 10 мг n10, n10 (1х10), n20 (2х10), n30 (3х10) (упаковки контурные ячейковые) - Антигипертензивное средство (ингибитор АПФ)

Беларусь - русский - Министерством здравоохранения Республики (Центр экспертиз и испытаний в здравоохранении)

sandoz pharmaceuticals d.d., Словения - ramipril, amlodipine, hydrochlorothiazide - ramipril, amlodipine and hydrochlorothiazide

Израиль - русский - Ministry of Health

sanofi - aventis israel ltd - hydrochlorothiazide 12.5 mg; ramipril 2.5 mg - tablets - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

Израиль - русский - Ministry of Health

teva pharmaceutical indust.ltd - ramipril 5 mg - tablets - ramipril - - hypertension - congestive heart failure - reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.